AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
05 Feb 2015 07:02 AM
RNS
AZ to acquire Actavis' US respiratory portfolio
05 Feb 2015 07:00 AM
RNS
Final Results
04 Feb 2015 09:00 AM
RNS
Notice of Results
02 Feb 2015 02:00 PM
RNS
Total Voting Rights
22 Jan 2015 07:00 AM
RNS
MAA FOR GOUT TREATMENT LESINURAD ACCEPTED BY EMA
14 Jan 2015 07:43 AM
RNS
BRILINTA PEGASUS STUDY MEETS PRIMARY ENDPOINT
02 Jan 2015 02:00 PM
RNS
Total Voting Rights
19 Dec 2014 05:40 PM
RNS
LYNPARZA APPROVED BY THE US FDA
18 Dec 2014 07:00 AM
RNS
LYNPARZAT APPROVED IN THE EUROPEAN UNION
09 Dec 2014 07:00 AM
RNS
MOVENTIG approved in the EU for OIC
05 Dec 2014 05:03 PM
RNS
Jury verdict favours AZ in Nexium litigation
02 Dec 2014 07:00 AM
RNS
New Drug Application for IRESSA accepted by US FDA
01 Dec 2014 02:00 PM
RNS
Total Voting Rights
01 Dec 2014 02:00 PM
RNS
Blocklisting Interim Review
26 Nov 2014 07:00 AM
RNS
POSITIVE RESULTS FROM BRODALUMAB PHASE III STUDY
24 Nov 2014 04:00 PM
RNS
Publication of Final Terms
24 Nov 2014 07:00 AM
RNS
DUAKLIR GENUAIR APPROVED IN THE EU FOR COPD
19 Nov 2014 05:00 PM
RNS
Launch and Pricing of a ?750m Bond
18 Nov 2014 07:00 AM
RNS
AZ strategy on track to deliver growth and value
17 Nov 2014 04:00 PM
RNS
Publication of Supplementary Prospectus
12 Nov 2014 07:00 AM
RNS
AMGEN & AZ POSITIVE PHASE III BRODALUMAB RESULTS
10 Nov 2014 02:27 PM
RNS
Director/PDMR Shareholding
06 Nov 2014 07:04 AM
RNS
ASTRAZENECA TO DIVEST MYALEPT TO AEGERION
06 Nov 2014 07:00 AM
RNS
3rd Quarter Results
06 Nov 2014 07:00 AM
RNS
3rd Quarter Results
05 Nov 2014 07:00 AM
RNS
Notice of Results
04 Nov 2014 07:00 AM
RNS
MEDIMMUNE ACQUIRES DEFINIENS
03 Nov 2014 03:00 PM
RNS
Total Voting Rights
03 Nov 2014 07:00 AM
RNS
AZ COMPLETES STRATEGIC TRANSACTION WITH ALMIRALL
30 Oct 2014 07:00 AM
RNS
US FDA APPROVES ONCE-DAILY XIGDUOT XR TABLETS
24 Oct 2014 12:10 PM
RNS
Olaparib receives positive CHMP opinion
02 Oct 2014 03:30 PM
RNS
Director/PDMR Shareholding
01 Oct 2014 04:00 PM
RNS
Total Voting Rights
29 Sep 2014 07:00 AM
RNS
ASTRAZENECA UPDATES ON ONCOLOGY PIPELINE AT ESMO
26 Sep 2014 11:15 AM
RNS
Positive CHMP Opinion for MOVENTIG (naloxegol)
16 Sep 2014 04:27 PM
RNS
FDA Approves MOVANTIK (naloxegol) Tablets
16 Sep 2014 07:00 AM
RNS
AZ AND LILLY ALLIANCE TO DEVELOP BACE INHIBITOR
10 Sep 2014 04:30 PM
RNS
Director/PDMR Shareholding
01 Sep 2014 04:00 PM
RNS
Total Voting Rights
19 Aug 2014 07:00 AM
RNS
US DOJ Closes Investigation into Plato
19 Aug 2014 07:00 AM
RNS
CAZ-AVI PHASE III RESULTS
14 Aug 2014 07:00 AM
RNS
TRALOKINUMAB PHASE III START IN SEVERE ASTHMA
13 Aug 2014 07:00 AM
RNS
PHASE III RESULTS LESINURAD COMBINATION THERAPY
04 Aug 2014 01:00 PM
RNS
Director/PDMR Shareholding
01 Aug 2014 02:00 PM
RNS
Total Voting Rights
01 Aug 2014 11:30 AM
RNS
Director/PDMR Shareholding
31 Jul 2014 07:00 AM
RNS
AstraZeneca Pipeline
31 Jul 2014 07:00 AM
RNS
Second Quarter & Half Year Results 2014
30 Jul 2014 09:00 AM
RNS
Notice of Results
30 Jul 2014 07:00 AM
RNS
STRATEGIC RESPIRATORY TRANSACTION WITH ALMIRALL
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100